Aging and bone loss: new insights for the clinician

doi:10.1177/1759720X11430858

. 2012 Apr;4(2):61-76.

doi: 10.1177/1759720X11430858.

Aging and bone loss: new insights for the clinician

Oddom Demontiero, Christopher Vidal, Gustavo Duque

PMID: 22870496
PMCID: PMC3383520
DOI: 10.1177/1759720X11430858

Aging and bone loss: new insights for the clinician

Oddom Demontiero et al. Ther Adv Musculoskelet Dis. 2012 Apr.

. 2012 Apr;4(2):61-76.

doi: 10.1177/1759720X11430858.

Authors

Oddom Demontiero, Christopher Vidal, Gustavo Duque

PMID: 22870496
PMCID: PMC3383520
DOI: 10.1177/1759720X11430858

Abstract

It is well known that the underlying mechanisms of osteoporosis in older adults are different than those associated with estrogen deprivation. Age-related bone loss involves a gradual and progressive decline, which is also seen in men. Markedly increased bone resorption leads to the initial fall in bone mineral density. With increasing age, there is also a significant reduction in bone formation. This is mostly due to a shift from osteoblastogenesis to predominant adipogenesis in the bone marrow, which also has a lipotoxic effect that affects matrix formation and mineralization. We review new evidence on the pathophysiology of age-related bone loss with emphasis upon the mechanism of action of current osteoporosis treatments. New potential treatments are also considered, including therapeutic approaches to osteoporosis in the elderly that focus on the pathophysiology and potential reversal of adipogenic shift in bone.

Keywords: aging; elderly; osteoblast; osteoclast; osteoporosis; treatment.

PubMed Disclaimer

Conflict of interest statement

Dr Duque has served as a consultant for Sanofi-Aventis, Novartis, and Servier pharmaceuticals. He is regular speaker for Sanofi-Aventis, Amgen, and Servier Pharmaceuticals and has received research grants from Merck, Novartis, Sanofi-Aventis, and Key Pharmaceuticals.

Cited by

Proglucagon-Derived Peptides as Therapeutics.
Lafferty RA, O'Harte FPM, Irwin N, Gault VA, Flatt PR. Lafferty RA, et al. Front Endocrinol (Lausanne). 2021 May 18;12:689678. doi: 10.3389/fendo.2021.689678. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34093449 Free PMC article. Review.
Emerging Role of ¹⁸F-NaF PET/Computed Tomographic Imaging in Osteoporosis: A Potential Upgrade to the Osteoporosis Toolbox.
Sheppard AJ, Paravastu SS, Wojnowski NM, Osamor CC 3rd, Farhadi F, Collins MT, Saboury B. Sheppard AJ, et al. PET Clin. 2023 Jan;18(1):1-20. doi: 10.1016/j.cpet.2022.09.001. PET Clin. 2023. PMID: 36442958 Free PMC article. Review.
Serum Uric Acid Level Is Positively Associated With Higher Bone Mineral Density at Multiple Skeletal Sites Among Healthy Qataris.
Ibrahim WN, Younes N, Shi Z, Abu-Madi MA. Ibrahim WN, et al. Front Endocrinol (Lausanne). 2021 Mar 31;12:653685. doi: 10.3389/fendo.2021.653685. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33868180 Free PMC article.
BMAL1-TTK-H2Bub1 loop deficiency contributes to impaired BM-MSC-mediated bone formation in senile osteoporosis.
Jinteng L, Peitao X, Wenhui Y, Guiwen Y, Feng Y, Xiaojun X, Zepeng S, Jiajie L, Yunshu C, Zhaoqiang Z, Yipeng Z, Zhikun L, Pei F, Qian C, Dateng L, Zhongyu X, Yanfeng W, Huiyong S. Jinteng L, et al. Mol Ther Nucleic Acids. 2023 Feb 16;31:568-585. doi: 10.1016/j.omtn.2023.02.014. eCollection 2023 Mar 14. Mol Ther Nucleic Acids. 2023. PMID: 36910712 Free PMC article.
Effects of Posture and Walking on Tibial Vascular Hemodynamics Before and After 14 Days of Head-Down Bed Rest.
Hedge ET, Vico L, Hughson RL, Mastrandrea CJ. Hedge ET, et al. JBMR Plus. 2023 May 2;7(7):e10756. doi: 10.1002/jbm4.10756. eCollection 2023 Jul. JBMR Plus. 2023. PMID: 37457881 Free PMC article.

See all "Cited by" articles

References

1. Adachi J., Saag K., Delmas P., Liberman U., Emkey R., Seeman E., et al. (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44: 202–211 - PubMed
1. Akune T., Ogata N., Hoshi K., Kubota N., Terauchi Y., Tobe K., et al. (2002) Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J Cell Biol 159: 147–156 - PMC - PubMed
1. Amin S., Riggs B., Melton L.J., III, Achenbach S., Atkinson E., Khosla S. (2007) High serum IGFBP-2 is predictive of increased bone turnover in aging men and women. J Bone Miner Res 22: 799–807 - PubMed
1. Atkins G., Welldon K., Halbout P., Findlay D. (2009) Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 20: 653–664 - PubMed
1. Balemans W., Ebeling M., Patel N., Hul E. V., Olson P., Dioszegi M., et al. (2001) Increased bone density in sclerostin is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10: 537–543 - PubMed

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database

[1] Adachi J., Saag K., Delmas P., Liberman U., Emkey R., Seeman E., et al. (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44: 202–211 - PubMed

[2] Adachi J., Saag K., Delmas P., Liberman U., Emkey R., Seeman E., et al. (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44: 202–211 - PubMed

[3] Akune T., Ogata N., Hoshi K., Kubota N., Terauchi Y., Tobe K., et al. (2002) Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J Cell Biol 159: 147–156 - PMC - PubMed

[4] Akune T., Ogata N., Hoshi K., Kubota N., Terauchi Y., Tobe K., et al. (2002) Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J Cell Biol 159: 147–156 - PMC - PubMed

[5] Amin S., Riggs B., Melton L.J., III, Achenbach S., Atkinson E., Khosla S. (2007) High serum IGFBP-2 is predictive of increased bone turnover in aging men and women. J Bone Miner Res 22: 799–807 - PubMed

[6] Amin S., Riggs B., Melton L.J., III, Achenbach S., Atkinson E., Khosla S. (2007) High serum IGFBP-2 is predictive of increased bone turnover in aging men and women. J Bone Miner Res 22: 799–807 - PubMed

[7] Atkins G., Welldon K., Halbout P., Findlay D. (2009) Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 20: 653–664 - PubMed

[8] Atkins G., Welldon K., Halbout P., Findlay D. (2009) Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int 20: 653–664 - PubMed

[9] Balemans W., Ebeling M., Patel N., Hul E. V., Olson P., Dioszegi M., et al. (2001) Increased bone density in sclerostin is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10: 537–543 - PubMed

[10] Balemans W., Ebeling M., Patel N., Hul E. V., Olson P., Dioszegi M., et al. (2001) Increased bone density in sclerostin is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10: 537–543 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Aging and bone loss: new insights for the clinician

Aging and bone loss: new insights for the clinician

Authors

Abstract

Conflict of interest statement

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Other Literature Sources